PMC 17/013| TROG 17.05 AZTEC: A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple-Negative Breast Cancer - Results (Cat C, Closed) (#23)
Steven David
1
- Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Content is not available at the time of publishing.